Immobilized human Her2 at 0.5 μg/ml (50μL/well) can bind to Pertuzumab with a linear range of 1.221 ng/ml to 5 μg/ml.
Product Details
Product Details
Product Specification
| Host | Human |
| Synonyms | Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein (MLN 19), Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, CD340, ERBB2, MLN19, NEU, NGL |
| Accession | P04626 |
| Clone Number | S-SC018 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG1,k |
| Application | Blocking of HER2 signaling Functional assays |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| ELISA | 1.221-5000 ng/ml |
Background
Pertuzumab is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer. It is the first-in-class of a kind of drug called a "HER dimerization inhibitor" — it inhibits the dimerization of HER2 with other HER receptors, which prevents them from signalling in ways that promote cell growth and proliferation.
Picture
Picture
ELISA
